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Intellectual disability (ID) has an estimated 
prevalence of 2 - 3% in developed countries, but the 
prevalence of ID and its epidemiology in developing 
countries is not well established.[1] However, a study 
in a rural South African (SA) population reported the 
prevalence to be 3.6%.[2] The most common cause of ID in SA is fetal 
alcohol syndrome, which occurs at the highest rate in the world and 
at epidemic proportions in some communities in the Western Cape 
Province.[3] Fragile X syndrome (FXS) is the most common inherited 
cause of ID in all populations.
FXS is an X-linked neurodevelopmental disorder, with a variable 
phenotype in males and females, associated with intellectual, physical 
and behavioural features. ID is the most consistent feature, ranging 
from mild to severe, while the other clinical features include 
developmental delay, long narrow face, large prominent forehead 
and chin, protruding ears, macro-orchidism in post-pubertal males, 
hyperactivity, hand flapping, attention deficit and autism.[4] FXS is 
estimated to have a prevalence of approximately 1/4 000 in males and 
1/8 000 in females worldwide.[5]
Almost all cases of FXS are caused by the expansion of a CGG repeat 
in the 5' untranslated region of the fragile X mental retardation gene 
(FMR-1) (OMIM #309550) at the FRAXA fragile site Xq27.3. A small 
number of deletions and missense mutations have also been reported. 
The CGG repeat size varies from 5 to 44 repeats in unaffected 
individuals. Intermediate (IM) alleles (‘gray zone’) range from 45 
to 54 CGG repeats. The clinical significance of carrying an allele in 
this size range is unclear. Premutation (PM) carriers have expansions 
of 55 to 200 repeats, which are not associated with ID. Affected 
individuals have >200 CGG repeats and are classified as having a 
full mutation (FM) which is associated with hypermethylation of an 
upstream gene promoter region (CpG island) and silencing of FMR-1 
gene transcription which results in the absence of the gene product, 
fragile X mental retardation protein (FMRP).[6]
FMR-1-related disorders include FXS and two other clinically 
distinct conditions, fragile X-associated tremor/ataxia syndrome 
(FXTAS) (OMIM #300623) and FMR-1-related primary ovarian 
insufficiency (FXPOI) (OMIM #311360). Both males and females 
with a PM in FMR-1 have an increased risk of developing FXTAS, 
a progressive neurodegenerative disorder with a prevalence of 45% 
reported in males older than 50 years of age. Female PM carriers 
are less likely to develop FXTAS but have a 21% risk of developing 
primary ovarian insufficiency (POI) (menopause before the age of 
40 years).[6]
The FMR-1 gene, identified in 1991, is 38 kb long and consists of 
17 exons which are alternatively spliced. It codes for the cytoplasmic 
protein FMRP, a 631 amino acid RNA-binding protein that is 
expressed in almost every tissue, with highest levels observed in 
the brain and testes. FMRP has been shown to down-regulate the 
translation of specific target messenger RNAs and plays a vital role 
in synaptic plasticity.[7]
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Background. Fragile X syndrome (FXS), the most common inherited cause of intellectual disability (ID) worldwide, is caused by the 
expansion of a CGG repeat in the fragile X mental retardation gene (FMR-1) gene.
Objectives. To review, retrospectively, the genetic services for FXS and other FMR-1-related disorders – including fragile X-associated 
tremor/ataxia syndrome (FXTAS) and FMR-1-related primary ovarian insufficiency (POI) – at the Division of Human Genetics, 
Johannesburg, for diagnostic, carrier and prenatal genetic testing. 
Methods. The records of 2 690 patients who had genetic testing for FMR-1 between 1992 and 2012 were reviewed. Of these, 2 239 had 
diagnostic testing, 430 carrier or cascade testing and 17 prenatal testing for FXS. Four had FXTAS or POI testing. Polymerase chain reaction 
(PCR) and/or Southern blotting techniques were used to test the patients’ samples for FMR-1 and FMR-2 expansions.
Results. Of the 2 239 patients who had diagnostic FMR-1 testing, 128 (5.7%) had a full mutation, 12 (0.5%) had a premutation and 43 
(1.9%) an intermediate allele. In 17 prenatal tests, eight fetuses tested positive for FXS. FMR-1 CGG repeat distribution analysis in 1 532 
males negative for the FMR-1 expansion showed that 29 and 30 CGG repeats were the most common (61.1%), but the distribution was 
significantly different in the black and white populations.
Conclusion. The findings support the presence of FXS, as the most common cause of ID, in all local populations. The FMR-1 CGG repeat 
distribution varied from that found in other studies. The number of family members tested was relatively low suggesting that many at-risk 
individuals are not being referred.
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In 1981, the first SA cases of FXS were described in four families 
investigated by cytogenetic studies. Eleven affected males and one 
carrier female were found to have a fragile site on the X chromosome 
(fra(X)(q27)).[8] Cytogenetic detection of FRAXA is not reliable as 
a diagnostic test for FXS as it cannot differentiate between this and 
other fragile sites, such as FRAXD, FRAXE and FRAXF, and it is costly. 
Goldman  et  al. [9,10] presented the first molecular evidence that FXS 
occurs in the SA black ID population. They found nine (6.1%) FXS 
cases in 148 patients with ID, suggesting that the condition had been 
underdiagnosed in the past. 
DNA testing for FXS has been available in SA since 1994 at the 
Division of Human Genetics (DHG), National Health Laboratory 
Service (NHLS) and the University of the Witwatersrand, 
Johannesburg. Prior to this, the diagnostic test was based exclusively 
on cytogenetic detection of the FRAXA fragile site. Currently, testing 
is performed by duplex polymerase chain reaction (PCR) analysis to 
size the normal and lower PM FMR-1 alleles, followed by Southern 
blotting to confirm expansions. The PCR assay is reliable, relatively 
cheap, and an efficient test as a primary screen for FXS. Mosaic males 
with a normal allele and an FM will yield a false-negative result. 
Objective
To review and analyse the findings from DNA testing for diagnostic, 
carrier and prenatal purposes for FXS and other FMR-1-related 
disorders, conducted at the DHG over a 20-year period. The study 
provided a follow-up to a previous study by Goldman[11] in which FXS 
testing was evaluated by the DHG. The presence of FRAXE mutations 
and the distribution of FMR-1 and FMR-2 repeat sizes in the ID cohort 
negative for FXS were also determined as part of the present study.
Methods
Subjects
Patients tested for FXS and FMR-1-related disorders
A total of 2 690 individuals from 2 243 families underwent genetic 
testing for FXS and other FMR-1-associated disorders through the 
DHG during the 20-year period (January 1992 - July 2012). Of these, 
2 239 unrelated individuals (887 white, 959 black, 211 mixed ancestry 
and 182 Indian) had a suspected diagnosis of FXS or ID of unknown 
cause (1  961 males and 278 females), 430 were extended family 
members referred for FXS carrier or diagnostic testing (mothers 
of affected individuals, siblings and other at-risk second and third-
degree relatives), four requested POI or FXTAS testing, and 17 were 
prenatal samples (obtained by chorionic villus sampling (CVS) or 
amniocentesis) from at-risk pregnancies.
The majority of referrals were from the Assessment and Learning 
Clinics at the Johannesburg (now the Charlotte Maxeke) Academic 
Hospital, Coronation (now Rahima Moosa) Hospital, Alexandra Clinic 
and institutions for people with ID. Further referrals were from local 
general practitioners, paediatricians and medical geneticists at the 
Genetic Counselling Clinics (at Chris Hani Baragwanath Academic 
Hospital, Johannesburg Hospital, Donald Gordon Medical Centre and 
Coronation Hospital) and genetic nurses. However, a small number 
of cases were referred from other genetic centres around SA and from 
doctors in private practice. Blood samples from the patients were sent 
in with a referral form stating the possible diagnosis and, in some cases, 
the clinical features observed. Information collected from patient files 
included (where available) each subject’s gender, ethnicity, their test 
results and pregnancy information (where applicable).
DNA extraction
Genomic DNA was extracted from whole blood using a salting 
out method or a commercial DNA extraction kit (High Pure PCR 
Template Preparation Kit, Roche Diagnostics) for blood samples 
<1 ml. DNA was extracted from CVS and amniocyte material using a 
phenol-chloroform extraction method.
PCR analysis
PCR amplification was performed using published primers[12,13] with 
detection of products on the ABI PRISM 377 or ABI 3130xl Genetic 
Analyzer (Applied Biosystems). Testing for AGG interruptions was 
not performed.
Southern blot analysis
Southern blot analysis was performed to establish the methylation 
status of the promoter region, to detect FMs that failed to amplify 
on PCR analysis and to differentiate females who were homozygous 
for a normal-sized FMR-1 allele from female PM/FM heterozygotes. 
Analysis of the FMR-1 expansion was carried out by digestion 
of genomic DNA (5 - 15 μg) with both EcoRI (Roche) and a 
methylation-sensitive enzyme, EclXI (Roche). Hybridisation was 
performed using the StB12.3 probe and labelled with the radionuclide 
isotope α-32PdCTP using the Megaprime DNA Labelling Systems kit 
(Amersham).
Results
FMR-1 expansion
Total cohort 
Of the 2 239 unrelated individuals with ID, 128 (5.7%) tested positive 
for the FMR-1 FM (117; 5.2% male and 11; 0.5% female probands). Of 
these, the FM was observed in 4.8% (43/887) of white patients, 5.2% 
(50/959) of black, 8.1% (17/211) of mixed ancestry and 9.9% (18/182) 
of Indian patients. Chi-squared analysis showed no significant 
difference (p=0.72) between the observed frequencies of FMs in the 
black and white populations (Table 1).
PMs accounted for 0.54% (12/2 239) of the total diagnostic cohort, 
ranging from 0% to 1% in the different ethnic groups tested; while IM 
alleles were observed in 1.8% (41/2 239) of the cohort, ranging from 
1.1% to 2.7% in the different ethnic groups tested.
Cascade testing
Of the 430 extended family members tested in the 2  243 families, 
an FM was found in 51 (11.8%; 22 males; 29 females) subjects, a 
PM and/or IM in 70 (16.3%; 59 females; 11 males) and 309 (71.9%) 
individuals tested negative.
FXTAS and POI referrals
A PM was found in 1/3 females tested, and one male referred for 
FXTAS tested negative.
Prenatal diagnostic testing
A total of 17 prenatal tests (12 white, four Indian, one black and none 
of mixed ancestry) were performed on CVS material or amniotic 
cells. Eight of the 17 (47%) fetuses had an FMR-1 FM (five male and 
three female), two a PM (one male and one female) and seven (41%) 
tested negative.
Incidental findings
Female siblings with FMR-1 expansions of both alleles
A large family positive for the FMR-1 expansion (n=24) was 
investigated and two female siblings were identified as having an 
FMR-1 expansion on both X chromosomes. Both siblings were found 
to have one IM allele of 51 CGG repeats and a second PM allele of 
57 repeats in one sibling and 69 repeats in the other. Both siblings 
inherited the 51 repeat unchanged from their father while the 57 
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repeat from their mother was inherited stably in one, but was shown 
to have expanded to 69 repeats in the other, and subsequently it 
expanded to an FM in her grandson.
FRAXE mental retardation syndrome
Amplification of the FMR-2 GCC repeat was used as an internal 
control primer in the PCR assay. An expansion of >200 GCC 
repeats in the FMR-2 gene at Xq28 has been shown to cause FRAXE 
syndrome (OMIM #309548), a rare condition associated with a 
mild form of ID.[14] Of the 1 961 males with ID tested on the duplex 
PCR assay, FMR-2 results were obtained for 1  558 subjects (who 
tested negative for the FMR-1 expansion). None were found to have 
an FMR-2 FM. However, an IM allele (26 - 59 GCC repeats) was 
observed in four males (0.3%). 
Distribution of FMR-1 CGG repeat sizes
The distribution of the CGG repeat size in 1 532 FMR-1 expansion-
negative ID subjects is shown in Fig. 1. The smallest FMR-1 CGG 
repeat size detected was 9. The most frequent repeat size observed 
was 29 CGG repeats (32.7%; 501/1 532) followed by 30 CGG repeats 
(28.4%; 435/1  532). CGG repeat sizes 20, 23, 24, 29, 30, 31 and 32 
together accounted for the majority (86%; 1 317/1 532) of alleles in 
the study population. The most common allele observed in the black 
and mixed-ancestry population was 29 CGG repeats (the frequency 
was 41%; 284/689 and 53/131, respectively), while 30 CGG repeats 
was the most common number in the white (34%; 207/606) and 
Indian populations (41%; 43/106). Chi-squared analysis showed a 
significant difference (p<10-5) in the frequency of the 29 and 30 CGG 
repeat sizes in the black and white populations.
Distribution of FMR-2 GCC repeat sizes
The distribution of the GCC repeat size in 1 558 FMR-1-expansion-
negative subjects is shown in Fig. 2. FMR-2 allele sizes ranged from 
5 to 40 GCC repeats, with 15 being the most common repeat size, 
accounting for 41% (640/1 558) of alleles identified. The distribution 
was evident in each of the four ethnic groups, and observed at a 
frequency of 33.8% (207/613) in whites, 48.7% (343/704) in blacks, 
37.6% (50/133) in mixed ancestry and 37% (40/108) in Indians. Chi-
squared analysis showed a significant difference (p<10-5) between the 
distributions of FMR-2 alleles in the black and white populations.
Discussion
The present study reviewed the molecular genetic testing for FXS and 
other FMR-1-related disorders conducted over a 20-year period at the 
DHG, NHLS, Johannesburg. 
In 2000, the PCR assay was introduced as an initial screen for 
the routine diagnosis of FXS. This has improved and refined the 
diagnostic testing by accurate determination of the FMR-1 CGG 
repeat size, which was not possible with Southern blotting. It has also 
reduced the number of Southern blots required and decreased the 
turnaround time for patients with CGG repeat sizes up to 120 repeats.
Full mutations in the total cohort
An FMR-1 FM was identified in 5.7% (128/2 239) of the probands 
tested, comparable with findings from ID cohorts worldwide 
which show FXS estimates ranging from 0.5% to 5%, depending 
on how cohorts were determined.[15] Our study provides further 
evidence to support that of Goldman et al.[9] that FXS, previously 
thought to be rare in the SA black population, is underdiagnosed. 
Table 1. Results from testing unrelated subjects with ID for FXS (N=2 239)
FMR-1 genotype*
White
(N=887), n
Black
(N=959), n
Mixed ancestry 
(N=211), n
Indian
(N=182), n
Total individuals 
(N=2 239), N (%)
FM            
Males EE 32 46 15 16 109
Mosaic males E + EE 2 2 2 1 7
EE + del 1 0 0 0 1
Females N/EE 8 2 0 1 11
Total, N (% of FM) 43 (4.8) 50 (5.2) 17 (8.1) 18 (9.9) 128 (5.7)
PM            
Males E 5 2 1 0 8
Females N/E 4 0 0 0 4
Total, N (% of PM)   9 (1) 2 (0.2) 1 (0.5) 0 (0) 12 (0.54)
IM allele            
Males I 18 7 3 3 31
Females N/I 6 4 0 0 10
Total, N (% of I)   24 (2.7) 11 (1.1) 3 (1.4) 3 (1.6) 41 (1.8)
N allele            
Males N 685 813 162 145 1 805
Females N/N 126 83 28 16 253
Total, N (% of N)   811 (91.4) 896 (93.4) 190 (90) 161 (88.5) 2 058 (91.9)
Total, n/N 811/887 896/959 190/211 161/182 2 058/2 239
ID = intellectual disability; FXS = fragile X syndrome; FM = full mutation; PM = premutation; IM = intermediate; N = normal.
*EE = full expansion: >200 CGG repeats; E = premutation: 55 - 200 CGG repeats; I = intermediate/gray zone: 45 - 54 CGG repeats; del= deletion; N = normal: 5 - 44 CGG repeats.
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FMs were observed in 5.2% (50/959) of 
all black subjects tested, which is slightly 
lower than that found in Goldman et al.’s 
small sample (nine affected in 148 patients; 
6.1%), but may be considered to be a more 
accurate reflection due to the larger sample 
involved. This result lends further support 
to the findings of Goldman et al.[9] that FXS 
is a common cause of ID in all SA ethnic 
groups. 
In the Indian population, FMs were 
found in 9.9% (18/182) of referrals for ID, 
which is higher than that observed in the 
other three ethnic groups. The majority 
of these Indian probands were referred 
from KwaZulu-Natal, and a selection bias is 
possible, as testing is expensive and referrals 
may be limited to patients with a high 
clinical suspicion of FXS. Interestingly, 
studies in the Indian population on the 
Indian subcontinent report a frequency of 
approximately 7.48% for FXS FMs,[16] which 
is lower than the frequency observed in the 
present study but higher than worldwide 
figures. The frequency of FMs in the mixed-
ancestry population was 8.1%, which is 
also higher than the frequency observed in 
the white and black ethnic groups, but the 
sample size was small and the differences 
were not statistically significant.
Premutations and intermediate 
alleles in the ID cohort
In the total cohort, a PM was detected 
in 0.54% (12/2  239) while an IM allele 
was detected in 1.83% (41/2  239). Both 
PMs and IM alleles were observed at higher 
frequencies within the white ID population 
(1% and 2.7%, respectively) compared with 
the other populations. PMs are estimated 
to occur in the general population at a 
prevalence of ~1/113 - 1/259 among females 
(~0.5%) and ~1/260 - 1/800 (~0.2%) among 
males; i.e. much more common than FXS 
(1/4 000 males).[4] Further, a significant excess 
of IM alleles in boys with special education 
needs compared with normal controls has 
been reported. There is controversy around 
whether or not males and females with 
a PM have subtle behavioural or learning 
difficulties. However, a number of studies 
have suggested that there is no clinical 
significance to the presence of PMs or IMs 
in individuals with ID.[17]
Cascade screening of extended family 
members detected an additional 121 
subjects with an FMR-1 FM, including 
mothers of affected individuals, siblings 
and other at-risk second- and third-degree 
relatives. As the FMR-1 mutation is rarely 
a new mutation, cascade screening from 
a proband is very worthwhile as it often 
detects other affected individuals in a family. 
The number of family members tested by 
cascade screening in the present study was 
low, suggesting that many at-risk family 
members are not being tested and/or offered 
appropriate genetic counselling.
Female siblings with FMR-1 
expansions of both alleles
The family in which two females were found 
to have expansions of both alleles is the first 
such case described in SA and the fifth such 
family in the world.[18] Clinical data were 
not available on these females, but the two 
sisters would not be expected to present with 
ID. Mostly, studies have shown that females 
with two PMs do not have ID nor physical 
features typical of FXS, while those with one 
FM have characteristics typical of females 
with FXS.[18] They would be predicted to be 
at risk of POI and FXTAS, but the exact risk 
is unclear.
FRAXE syndrome
The present study confirms the rarity of 
FRAXE syndrome in SA, consistent with 
reports from other studies.[19] FRAXE 
syndrome has an estimated population 
prevalence of 1/23  500, based on two large 
population-based studies undertaken on 
special education needs individuals. A study 
on a cohort of white and African American 
subjects showed no FMR-2 expansion, while 
another report found one FRAXE syndrome-
positive subject among 3 731 boys with ID.[19] 
FRAXE screening is therefore not indicated 
and testing has not been implemented 
routinely in the DHG. Amplification of the 
FRAXE allele is, however, useful in the 
duplex PCR FRAX assay as a control for 
PCR failure, especially in males, and as an 
indicator of an FMR-1 expansion. Its value 
has also been demonstrated as a linked 
marker in tracking the FMR-1 expansion 
in families, especially in prenatal testing, as 
it may reduce the time taken to obtain an 
initial result. 
Distribution of FMR-1 alleles
Our study investigated the distribution of 
the CGG repeat in 1 532 FMR-1-expansion-
negative ID subjects. The CGG repeat 
sizes of 29 and 30 were found to be most 
common in all ethnic groups, together 
accounting for 61.1% of the alleles in the 
cohort and comparable with populations 
of western European ancestry and other 
populations in Asia, Indonesia, Brazil, 
Chile, Cameroon, Ghana and India, and in 
African Americans. [20] In the present study 
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Fig. 1. Distribution of FMR-1 CGG repeat sizes in subjects negative for the FMR-1 expansion (N=1 532).
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the 30 CGG repeat (found in 34% of cases) was the most common 
allele in the white population, which corroborates well with the 
39% frequency reported by Goldman.[11] The most common allele 
in the black population in this study was shown to be 29 CGG 
repeats (in 41% of the total black cohort). This finding differs from 
that of Goldman,[11] who showed that 28 CGG repeats (32%) was a 
common finding in SA black individuals. Our study is more likely 
to reflect the correct size as newer techniques have allowed for more 
accurate sizing. However, a study in a Cameroonian population 
also showed the 29 CGG repeat to be most common, whereas 
studies among African Americans and Ghanaians suggested that 
the 30 CGG repeat was the most common allele. Further studies are 
needed to distinguish true distribution differences from technical 
ones. Very few studies have been performed on African populations 
and the present study adds significantly to the African population 
data. 
Distribution of FMR-2 alleles
This is the first study conducted on SA males with ID which provides 
information on the range of the FMR-2 GCC repeat sizes. FMR-2 
allele distribution in most ID populations showed that the 15 GCC 
repeat was the most frequent allele, similar to that observed in our 
study. Four males in this sample were found to have an FMR-2 repeat 
size in the IM range. Studies have disputed the association of IMs 
with ID and suggested that more studies with larger numbers are 
needed to resolve this matter.[19]
Conclusion
This study strongly supports the fact that FXS is the most common 
cause of ID in all the local populations. However, FRAXE syndrome 
was not shown to contribute significantly to ID in the SA population 
and has therefore not been incorporated into the routine diagnostic 
testing. Earlier studies undertaken in our laboratory on X-linked 
mental retardation genes also suggested that mutations in ARX, XNP 
and HOPA like most others, are rare, and not significant contributors 
to ID locally.[21,22]
The presence of an FMR-1 expansion in a family member has 
significant implications, as there are likely to be other affected and at-risk 
relatives. A confirmed diagnosis leads to improved support for newly-
diagnosed patients and potentially allows identification of all the carriers 
in the family. Prenatal and pre-implantation genetic diagnosis can be 
offered to at-risk individuals and this service allows couples to make 
informed choices about their future. Attempts should be made to expand 
offers of cascade testing once a proband is diagnosed. Comprehensive 
genetic counselling services need to become more widely available so 
that they can assist affected families with these issues. 
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